CardiaTec secures $6.5M seed funding to accelerate its mission to combat cardiovascular disease using computational drug discovery.
A cardiovascular breakthroughs
Cambridge-based biotech company CardiaTec has announced a successful $6.5M seed funding round to drive forward its cutting-edge computational drug discovery platform, focusing on the biology of cardiovascular disease. Montage Ventures led the round, with support from Continuum Health Ventures, Laidlaw Ventures, APEX Ventures, and several prominent individual investors, including industry leaders Dr Maximilien Levesque and Naheed Kurji.
CardiaTec’s proprietary platform, which decodes cardiovascular disease biology using large-scale human multi-omics data, aims to address the global challenge of cardiovascular disease, responsible for 17.9 million deaths annually. The new funding will allow the company to advance its drug discovery efforts, pushing novel targets into preclinical development.
Raphael Peralta, CEO and co-founder of CardiaTec, shared: “Modelling complex cardiovascular disease biology across multiple omic dimensions has immense potential in unlocking new therapeutic strategies that will challenge the current standard of care. Over the last several years, I am proud of the team’s relentless drive to reach important milestones and our collective ambition to tackle a tough global problem.”
Building a data-driven solution to tackle the world’s leading killer
CardiaTec’s mission centres on using high-dimensional multi-omics data—spanning genomics, proteomics, epigenomics, and transcriptomics—to better understand the intricate biology underlying cardiovascular diseases. This computational approach, a key differentiator in drug discovery, aggregates vast data sets that traditional methods fail to manage efficiently.
The company has built a robust network of sixty-five hospitals across the US and UK, enabling the collection of human heart tissue to create the world’s largest human heart tissue multi-omics dataset. This groundbreaking initiative could provide critical insights into cardiovascular disease, offering new avenues for therapeutic innovation.
Todd Kimmel, Partner at Montage Ventures, emphasised the significance of CardiaTec’s approach: “CardiaTec is at the forefront of a new era in cardiovascular drug discovery. Their unique combination of the world’s largest multi-omics dataset from human cardiac tissues and advanced computational technology positions them to uncover novel drug targets for the world’s leading cause of death. With strong pharma industry connections, a growing market need, and a proprietary data moat, CardiaTec has the potential to revolutionise how we approach and treat cardiovascular diseases.”
With its computational platform and deep commitment to unlocking new therapeutic strategies, CardiaTec aims to close the innovation gap in cardiovascular disease treatment, an area where progress has traditionally lagged.
CardiaTec’s growing impact and industry recognition
Founded in 2021 as a spin-out from the Han Lab at the University of Cambridge, CardiaTec is led by Peralta, alongside co-founders Prof Namshik Han (CTO) and Thelma Zablocki (COO). The team has brought together experts from top organisations such as Bristol Myers Squibb, Cleveland Clinic, and Recursion Pharmaceuticals, with the founders also being recognised on the Forbes 30 Under 30 Europe list.
CardiaTec’s focus on cardiovascular disease—a long-neglected therapeutic area—comes at a time when computational drug discovery is increasingly recognised as the future of medicine. With this fresh infusion of $6.5M in seed funding, CardiaTec is well-positioned to make significant strides toward new treatments for the world’s leading cause of death.
